ArticleGut microbes2025
Multi-omics integration reveals functional signatures of gut microbiome in atherosclerosis.
Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- From molecules to medicine: the gut‒heart axis comes of age.Gut microbes · 2026Article
- Microbial metabolite-driven mechanisms linking the gut microbiome to atherosclerosis: multi-omic and translational perspectives.Gut microbes · 2026Review
- Multi-omics profiling of oral microbial functional signatures and systemic immune-metabolic features in perinatal depression.Brain, behavior, & immunity - health · 2026Article
- Gut microbiome dysbiosis, short-chain fatty acid depletion and implications for neuroinflammation in atypical parkinsonian syndromes - a systematic review of patient cohorts.Journal of Parkinson's disease · 2026Review
- Airway Microbiome Is Associated with Atherosclerosis in Adults from Southern Caribbean.Microorganisms · 2026Article
- Exploring the oral microbiome diversity and genus signatures associated with a novel non-invasive metabolic indicator: a cross-sectional study.The Saudi dental journal · 2026Article
- Targeting the Gut-Heart Axis in Diabetic Heart Failure: Microbiota and SGLT2is as Converging Therapeutic Frontiers.International journal of molecular sciences · 2026Review
- Targeting the gut microbiota: emerging strategies to enhance healing of diabetic foot ulcers.Frontiers in endocrinology · 2026Review
- Integrative transcriptome and microbiome analysis reveals ferroptosis-driven duodenal damage caused by Ochratoxin A in mice.Frontiers in immunology · 2026Article
- Microbiota-mediated mechanisms of natural products in atherosclerosis: focus on metabolic and inflammatory pathways.Frontiers in endocrinology · 2026Review
- Global research trends and hotspots evolution in type 2 diabetes mellitus complicated with coronary heart disease: a bibliometric analysis from 2016 to 2026.Frontiers in endocrinology · 2026Review
- Gut microbiota-immune crosstalk in childhood and adolescent obesity: mechanistic insights and therapeutic potential focused on short-chain fatty acids and emerging metabolites.Frontiers in microbiology · 2026Review
- The Endocannabinoid-Microbiota-Neuroimmune Super-System: A Unifying Feedback Architecture for Systems Resilience, Collapse Trajectories, and Precision Feedback Medicine.International journal of molecular sciences · 2025Review
- Preterm birth alters the gut microbiota, metabolome and health outcomes of twins at 12 months of age.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS), a predominant contributor to global cardiovascular disease burden, exhibits complex interplay with gut microbiota dysbiosis. While the associations between microbial imbalance and AS pathogenesis are well-documented, the pathophysiological mechanisms governing microbe-host crosstalk remain incompletely characterized. Current research limitations stem from methodological heterogeneity across studies and the absence of consensus regarding disease-specific microbial signatures. In this study, we conducted an integrated multi-omics analysis to characterize the functional signatures of gut microbiome in AS. We collected all public AS-related 6 microbiome datasets and 8 peripheral blood host transcriptomic datasets from across the world, comprising 456 metagenomic samples and 111 16S rRNA gene sequencing samples for microbial profiling, alongside 118 RNA-Seq samples and 302 microarray samples. We systematically characterized AS microbial taxa and computationally inferred the metabolic potential for the gut microbiome using metabolomic-related data. Metabolite-host gene interactions were further predicted based on the synergistic effects between microbiome and host transcriptome in AS. Five "microbe-metabolite-host gene" tripartite associations related to AS were identified involving 5 microbial genera (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.